Objective: To investigate the optimal treatment method and risk factor of neck node metastasis from unknown primary tumors (NUP) treated by radiotherapy. Methods: Retrospective case study based on a multi-institutional survey was conducted by the Japanese Radiation Oncology Study Group. Patients pathologically diagnosed as having NUP from 1998 to 2007 were identified. Univariate and multivariate analyses of overall survival (OS), progression free survival (PFS), neck progression free survival (NPFS) and mucosal progression free survival (MPFS) were evaluated. Results: In total, 130 patients with median age of 65 years were included. Nodal stages N1, N2a, N2b and N2c were observed for 10, 26, 43, 12 and 39 patients, respectively. All the patients received radiotherapy (RT) with neck dissection in 60 and with chemotherapy in 67 cases. The median doses to the metastatic nodes, prophylactic neck and prophylactic mucosal sites were 60.0, 50.4 and 50.4 Gy, respectively. The median follow-up period for surviving patients was 42 months. Among 12 patients, occult primary tumors in the neck region developed after radiotherapy. The 5-year OS, PFS, NPFS and MPFS were 58.1%, 42.4%, 47.3% and 54.9%, respectively. Univariate analysis showed that lower N stage (N1-2b), non-bulky node (<6 cm) and negative extracapsular extension (ECE) status were the factors associated with favorable OS, PFS, NPFS and MPFS. Radical surgery proved to be a favorable factor of OS, NPFS and MPFS. On multivariate analysis, lower N stage and negative ECE status were correlated with improved survival.
Introduction
Neck node metastasis from clinically unknown primary tumors (NUP) accounts for 2-7% of head and neck malignancies (1) (2) (3) . Radiotherapy for NUP is used to control both macroscopic and microscopic cervical lesions without subsequent development mucosal lesion. However, the optimal treatment method for NUP still remains unclear in some respects. The extent of radiotherapy (inclusion of contralateral cervical lymph node regions and/or mucosal region) and irradiated dosage is still controversial (3) (4) (5) (6) (7) (8) (9) (10) . Combination of chemotherapy has been established as the standard therapy of patients with locally advanced head and neck cancer, but the role of chemoradiotherapy for NUP has not yet been established (4, (11) (12) (13) (14) (15) (16) (17) . However, it is difficult to conduct randomized or prospective studies of this disease. The European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group conducted a randomized Phase III trial to compare different radiation therapy regimens in treating NUP patients; they tried to compare the disease-free survival of NUP patients treated with selective (i.e. ipsilateral neck) irradiation vs extensive (i.e. bilateral neck, and pharyngeal and laryngeal mucosa) irradiation (18) . However, this trial was prematurely closed because of insufficient patient accrual.
The purpose of this study was to investigate the optimal treatment method and risk factor of radiotherapy for NUP by analyzing the results of a retrospective national survey of radiotherapy for NUP patients treated from 1998 to 2007, which was conducted by the Japanese Radiation Oncology Study Group (JROSG).
Materials and methods
The Head and Neck committee of JROSG conducted the multiinstitutional survey by sending questionnaires to 18 institutes in Japan for this retrospective study. This study was performed according to the guidelines approved by the institutional review board of each institute. Patients pathologically diagnosed as having NUP (squamous cell carcinoma or undifferentiated carcinoma), who were treated by radiotherapy from 1998 to 2007, were identified. The lymph node stage was based on the UICC-TNM 7th edition. Those who had distant metastasis were excluded. The questionnaires includedage, sex and performance status (PS) of the patients; start and end date of radiotherapy; clinical and pathological N stage; number and maximum size of metastatic lymph nodes; involved lymph node levels; pathological status (i.e. extracapsular extension); tumor markers; diagnostic methods (CT, MR, US, PET/CT and fiberscope); combined therapies (surgery and/or chemotherapy); surgical procedures and purposes (radical, semiradical, palliative, diagnostic and planned surgery); chemotherapy contents (concurrent, neoadjuvant, adjuvant, preoperative, postoperative and alternative); purpose of radiotherapy (radical and palliative); radiation method, including range and dose of clinical target volume (local, ipsilateral or bilateral neck and mucosal region); adverse effects; treatment outcome; salvage therapy and double cancer. As for target volume, local irradiation means the irradiation only to the level of the involved nodes and ipsilateral irradiation means the irradiation to the prophylactic levels in addition to the level of involved nodes. No central histological review was performed for this study. Toxicities were evaluated using National Cancer Institute Common Toxicity Criteria version 4.0. Severe complications were defined as those necessitating hospitalization or surgical intervention, and/or resulting in death.
Based on the survival data from the questionnaires, 5-year overall survival (OS), progression free survival (PFS), neck progression free survival (NPFS) and mucosal progression free survival (MPFS) were estimated by using the Kaplan-Meier method. OS was defined as the time from treatment initiation to death from any cause. PFS was defined as the time from treatment initiation to disease progression or death from any cause. NPFS was defined as the time from treatment initiation to neck recurrence or death from any cause. MPFS was defined as the time from treatment initiation to emergence of mucosal lesion or death from any cause. Univariate and multivariate analysis were performed to evaluate the factors associated with those survival times; the factors included PS, extent of clinical target volume, treatment intent, N Stage (N1-2b vs N2c-N3), lymph node (LN) size, involved LN level (I-III vs IV-VI), irradiated dose to the involved nodes and prophylactic/mucosal regions, surgical procedure, ECE status and chemotherapy.
Statistical analysis was performed using JMP Pro version 11 (SAS Institute Inc., Cary, NC, USA). The log-rank test was used to compare differences between subgroups. The Chi-square test was used to investigate the relationship between variables. A P value of 0.05 indicated significance.
Results
Patient characteristics and treatment details are summarized in Tables 1 and 2 . CT-based three-dimensional RT was applied in 70.8% of all the patients. IMRT was not administered in this series.
The 5-year OS, PFS, NPFS and MPFS were 58.1%, 42.4%, 47.3% and 54.9%, respectively (Table 3 , Figs 1 and 2 ). Recurrence after initial treatment occurred at 1-122 months (median 8 months) in 12 mucosal regions (nine in-field, three out-of-field), 29 nodal regions (22 in-field, four out-of-field and three both in-and out-offield) and 31 distant metastases. Mucosal recurrences occurred most commonly in the oropharynx in six (four in-field, two out-of-field); other mucosal regions included the hypopharynx in two (all infield), hypopharynx/cervical esophagus in one (in-field), oral floor in one (in-field), buccal mucosa in one (out-of-field) and larynx in one (in-field). Nodal recurrences occurred at 2-67 months (median 9 months) after initial treatment. The sites of distant metastases were as follows: lung (15), bone (13), liver (6), pleura (1) and skin (1) .
Univariate analysis showed that lower N stage (N1-2b), non-bulky node (<6 cm) and ECE negative were factors associated with favorable OS, PFS, NPFS and MPFS (P < 0.05, Table 3 ). Radical surgery (modified radical neck dissection or selective neck dissection) also proved to be a factor for favorable OS, NPFS and MPFS. The median dose for palliative RT was significantly lower than for radical RT (median 34.0 Gy, range 30.0-75.9 Gy vs median 60.0 Gy, range 12.6-86.8 Gy) and the treatment outcome of palliative RT was significantly poor in OS, PFS and NPFS (Tables 2 and 3 ). There was no statistical difference in other factors (extent of clinical target volume, involved LN level, irradiated dose to the involved nodes and prophylactic/mucosal regions and chemotherapy). Multivariate analysis, which was conducted for variables that proved to be prognostic factors by univariate analysis, showed that lower N stage and negative ECE status was the factor correlated with favorable OS, PFS, NPFS and MPFS (P < 0.05, Table 4 ). Radical treatment correlated with favorable OS and radical surgery was correlated with favorable MPFS.
As for acute adverse events, Grade 3 mucositis was observed in 18 patients (combined with chemotherapy in 12) and Grade 3 dermatitis in eight (combined with chemotherapy in seven). As for severe late adverse events, Grade 3 laryngeal edema was observed in two patients. Only one patient developed Grade 4 brain infarction, possibly caused by the treatment.
Discussion
Radiotherapy, as well as surgery, is considered to be an important option to control NUP. The optimal method of radiotherapy for NUP had been controversial for a long time, as it is difficult to conduct randomized or prospective studies of this rare disease (18) . Some case studies have revealed therapeutic outcomes of NUP treated by radiotherapy combined with surgery and/or chemotherapy, which are summarized in Table 5 (3, 6, 9, 11, 16, 17, (19) (20) (21) . Prognostic factors for survival are reported to be nodal stages, number of positive nodes, neck dissection, histopathological grading and ECE (3) (4) (5) 7, 9, 19, 20, 22, 23) . In this series, the 5-year OS rate was 58.1%, similar to the data in the previous studies. On univariate analysis, favorable OS, PFS, NPFS and MPFS were associated with lower N stage (N1-2b), non-bulky node (<6 cm) and negative ECE status. On multivariate analysis, lower N stage and ECE status was correlated with improved survival. The results are also consistent with those of previous reports (3) (4) (5) 12, 20, 22) . The current National Comprehensive Cancer Network (NCCN) guidelines for NUP (Version 1. 2017) provide recommendation for treatment with neck dissection especially in N1 disease (Category 2A). After neck dissection, treatment strategies are determined by lymph node status. Definitive RT or observation is recommended in N1 without ECE (Category 2A). In the case of N2 or N3 without ECE, definitive RT or chemoradiation therapy is recommended (Category 2B). In the case of ECE, chemoradiation is recommended (Category 1). Definitive radiotherapy without surgery is recommended for N1 (Category 2B) and chemoradiation is recommended for N2 or N3 (Category 2B). Induction chemotherapy followed by systemic chemoradiation therapy is regarded as category 3.
Unfortunately, there are some limitations in this series. The availability of FDG-PET was low (31%) and the examination by NBI was not introduced. These diagnostic procedures have been developed and enabled the detection of early head and neck cancers. FDG-PET/CT has demonstrated relatively high detection rates about 40% of NUP (24) . The usefulness of NBI with magnifying endoscopy for detecting the primary site of NUP also has been reported. Hayashi et al. investigated 46 patients of NUP and 26 lesions were suspected to be cancerous lesions (25) . Of 26 patients, 16 lesions in 16 patients (35%, 16/46) were identified to be squamous cell carcinoma. Another paradigm for the diagnosis and management of NUP was reported using transitional robotic surgery. Mehta et al. reported 10 patients underwent transoral robotic base of tongue CT, computed tomography; MR, magnetic resonance; FDG-PET, 18-fluoro-deoxyglucose positron emission tomography. resection (26) . All patients underwent a cervical biopsy, PET/CT, formal endoscopy and bilateral tonsillectomy before this procedure but not identified primary lesion. In nine of 10 patients, pathologic examination revealed invasive squamous cell carcinoma with a mean diameter of 0.9 cm. Recently, TNM classification of Malignant Tumours 8th edition was published. In this new classification, NUP was classified in three categories; EBV or HPV/p16 negative or unknown, HPV/p16 positive and EBV positive. If EBV was positive, it was staged as nasopharyngeal carcinomas and if p16 was positive, it was staged as p16 positive oropharynx carcinomas. Treatment strategy for NUP is considered to be subdivided by EBV or HPV/p16 status. Unfortunately, we would not apply this new TNM classification in present analysis because EBV and HPV/p16 status was not available in many cases. When we conducted this study, EBV or HPV/p16 status was not routinely examined. In addition, TNM classification is a bland-new classification, thus, we could not fully validate the outcome to reported series.
One of the concerns of NUP treatment is the extent of the irradiation field. It has been disputed as to whether contralateral neck and/or potential primary site should be included or not. In our series, there were no significant differences in OS, PFS, NPFS and MPFS in different irradiation fields. Reddy et al. reported that subclinical metastases in the contralateral cervical lymph nodes were better controlled by irradiation, including bilateral neck and pharyngeal mucosa than ipsilateral neck irradiation (86% vs 56%, P = 0.03) (10) . The occult primary emerged in 8% after bilateral irradiation and in 44% after ipsilateral irradiation (P = 0.0005). This difference was anticipated to the fact that the mucosal region was contained in irradiated fields in the bilateral group. Strojan et al. reported the comparison between involved-field and extended-field in postoperative setting (27) . In multivariate analysis, the only factor that influenced locoregional control was the patients' age with older patients and the extent of RT field did not influence on any outcome. In addition, acute and late toxicity was more common in patients with extended-field RT. They concluded Involved-field RT, although not superior over extended-field RT, seems to be a preferred treatment option due to significantly reduced toxicity and better prospects for successful salvage in case of contralateral neck recurrence or emergence of mucosal primary in the pharyngolaryngeal axis.
The rate of metachronous emergence of the primary site was 9.2% (12/130) in our series; the results were consistent with those of the previous reports (3,6,9,16,19,20) . Erkal et al. reported that 12 of 126 patients (10%) developed squamous cell carcinoma in the head and neck mucosa after initial treatment (9) . In the review of Nieder et al., the median rate of emergence of the primary site after extensive radiotherapy was 9.5% (range 2-13%), whereas it was 8.0% (range 5-44%) after ipsilateral radiotherapy (8) . As will be discussed later, IMRT with appropriate mucosal irradiation field settings is considered to lead to better treatment outcome by controlling the occult mucosal lesions.
In our series, the group that received (modified) radical neck dissection had better outcomes than the group without neck dissection in terms of OS, NPFS and MPFS on univariate analysis (P < 0.05). Neck dissection followed by postoperative radiotherapy is generally recognized as a standard approach, and also has a clear advantage in evaluation for accurate disease extension and histopathological features, such as ECE, thus providing additional information to decide appropriate adjuvant therapeutic strategies such as combination with chemotherapy. In our series, negative ECE status proved to be a favorable prognostic factor in OS, PFS, NPFS and MPFS. Coster et al. reported clinical results of 24 patients with NUP treated with curative resection by neck dissection or excisional biopsy alone; ECE proved to be an unfavorable prognostic factor of neck recurrence, cause-specific survival and OS (19) . They concluded that patients with N1 disease without ECE could be managed by surgery alone, while patients with N2 or higher nodal stage disease, and/or ECE would be candidates for postoperative adjuvant radiation therapy. Although IMRT was not administered in this series, it is considered to be a promising procedure in treatment for NUP by offering appropriate target volume coverage while sparing organs-at-risk compared with conventional radiotherapy (11) (12) (13) 15, 21, 28, 29) . Villeneuve et al. reported promising results of NUP using the IMRT technique (11) . They treated 25 patients with IMRT by a median dose of 70 Gy with a radiation field including the bilateral neck and ipsilateral pharyngeal mucosa; 17 underwent IMRT for definitive intent, eight received it for postoperative setting, and 18 patients received platinum-based concurrent chemotherapy. With a median follow-up of 38 months, OS, disease-free survival and locoregional control rates were all 100% at 3 years with no emergence of primary cancer. Nine patients (36%) developed Grade 2 or greater xerostomia at 6 months, but only 2 (8%) of them developed the same grade of salivary toxicity after 24 months of follow-up. They concluded concurrent chemoradiotherapy with IMRT, including bilateral neck and ipsilateral putative pharyngeal mucosa, as the optimal therapeutic strategy. Janssen et al. reported individualized IMRT treatment approach to avoid extensive volumes while treating patients without oncological compromise (30) . Ipsilateral irradiation was preferred and treatment fields to the putative mucosal site or the contralateral neck were enlarged based on individual risk factors including clinical, surgical, histopathological and imaging information. The 3-year mucosal control rate, nodal control rate and distant metastasis free survival were 100%, 93%, and 88%, respectively and there were no Grade 2 or more late complications.
The role of adding systemic chemotherapy for improving local and distant control is another important issue. In our present series, the combination of chemotherapy did not show advantages for improving OS, PFS, NPFS or MPFS. Argiris et al. reported a series of 25 patients who received concurrent chemoradiotherapy for N2 or N3 stage NUP (17) . Although this study was a retrospective analysis with a small sample size, they concluded that the addition of systemic chemotherapy may lead to improved locoregional and distant control, and long-term survival for good PS patients with Stage IV (N2 or N3) NUP. On the other hand, Chen et al. found no advantage of concurrent chemotherapy with regard to OS, PFS or locoregional control in a retrospective analysis of 60 patients treated by radiotherapy, of whom the majority (70%) underwent neck dissection (14) .
The all concerns about NUP treatment strategy would be examined along with the new UICC/AJCC 8th TNM classification, EBV and HPV/p16 status should be required for accurate staging. Indeed, we do appreciate further investigation based on the 8th TNM classification should be desirable.
Conclusion
Our results suggest lower nodal stage, negative ECE status and combination of radical surgery showed a favorable impact on survival and disease control in patients with NUP treated by radiotherapy. There were no significant differences in OS, PFS, NPFS and MPFS in different irradiation fields.
